• Hemex Health

  Participated · Equity · Jun 2017

  Hemex Health develops compact diagnostic devices—a Magneto-optical device for malaria and a Hemechip for hemoglobin disorders—that return results from a pinprick of blood in minutes. The devices use disposable cartridges, can wirelessly transmit results, and are designed to be used by primary care providers rather than specialists. The company emphasizes affordability and accessibility to expand testing in resource-limited settings. Hemex was founded in 2016 by Patti White and Peter Galen and is headquartered in the OTRADI Bioscience Incubator in Portland, Ore. The startup employs eight staff and reports a board and scientific advisors spanning four continents. Current prototypes are in clinical trials and the company plans to finalize product design, manufacturing, and distribution as it scales testing.

• Cadence Biomedical

  Participated · Series A · Apr 2012

  Cadence Biomedical makes the Kickstart device, which uses an Exotendon system of pulleys and springs (no motors or batteries) to capture energy during a step and assist stability, leg advancement and gait cues. The device is intended to accelerate recovery to walking for stroke survivors and patients with other neurological conditions. The company says clinical partners report patients reaching new levels of independence and faster rehabilitation outcomes. Cadence will use the new funding to expand its sales, marketing and reimbursement efforts and to grow its clinical footprint. Barry Hix joined as CEO in November, and COO Brian Glaister founded the company in 2007 (originally Empowering Engineering Technologies). Financially, Cadence announced a $1.2 million Series B and has previously received a $1.0 million Department of Defense grant in 2013 and $1.1 million in funding in 2012. Cadence Biomedical develops the Kickstart Walking System, a non-robotic device that uses natural spring tension to capture energy and provide walking assistance. The Kickstart has been on the market since last September and is prescribed by physicians and custom fitted by orthotists. The company plans to use new funding to develop technologies to help amputees learn to walk with their prostheses. Cadence received a $1 million grant from the Department of Defense to advance this work. The company raised $1.1 million in an oversubscribed funding round last year. Cadence was founded in 2007; CEO Brian Glaister is a Seattle entrepreneur and former Technology Commercialization Fellow at the University of Washington’s Center for Commercialization. Cadence Biomedical is a medtech company. According to a regulatory filing dated Feb. 28, 2013 and reported April 12, 2013, the company raised $1.3 million. The financing comprised equity, options and warrants. Forty-eight investors participated in the raise. The filing lists $0 in sales commissions and $0 in finders' fees. The article does not provide details about the company's products, operations, or future plans. No revenue, user, founding‑year, or location information is reported. Cadence Biomedical is a Seattle-based medical device company developing Kickstart, a Kinetic Orthosis that amplifies existing strength to help people with severe disabilities walk. Kickstart uses no motors or batteries; a proprietary tuned system of pulleys and springs captures energy during the beginning of a step and returns it at the right moment to propel the user and lift the leg for the next step. That action can help many people with severe disabilities walk faster and farther, and allow some who would otherwise require wheelchairs to regain strength and coordination. The company says it is committed to helping the 2.3 million Americans who suffer severe mobility impairments. Cadence has been awarded grants from the National Institutes of Health and the Congressionally-Directed Medical Research Program. The recently closed oversubscribed $1.1 million Series A2 will support manufacturing and sales as Cadence releases Kickstart to the market.

No current team members are available.